GENMAB AS SP.ADR/1/10DK 1 - Asset Resilience Ratio

Latest as of December 2025: 0.00%

GENMAB AS SP.ADR/1/10DK 1 (GE91) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore how large is GENMAB AS SP.ADR/1/10DK 1's balance sheet for the complete picture of this company's asset base.

Liquid Assets

€0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

€12.87 Billion

≈ $15.05 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how GENMAB AS SP.ADR/1/10DK 1's Asset Resilience Ratio has changed over time. See GENMAB AS SP.ADR/1/10DK 1 balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down GENMAB AS SP.ADR/1/10DK 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GE91 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€0.00	0%
Total Liquid Assets	€0.00	0.00%

Asset Resilience Insights

Limited Liquidity: GENMAB AS SP.ADR/1/10DK 1 maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

GENMAB AS SP.ADR/1/10DK 1 Industry Peers by Asset Resilience Ratio

Compare GENMAB AS SP.ADR/1/10DK 1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	13.57%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	82.25%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for GENMAB AS SP.ADR/1/10DK 1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.00%	€0.00 ≈ $0.00	€12.87 Billion ≈ $15.05 Billion	--
2024-12-31	24.54%	€1.57 Billion ≈ $1.83 Billion	€6.39 Billion ≈ $7.47 Billion	-13.06pp
2023-12-31	37.60%	€1.97 Billion ≈ $2.30 Billion	€5.24 Billion ≈ $6.13 Billion	-3.67pp
2022-12-31	41.27%	€1.79 Billion ≈ $2.09 Billion	€4.33 Billion ≈ $5.07 Billion	-0.88pp
2021-12-31	42.15%	€1.58 Billion ≈ $1.85 Billion	€3.75 Billion ≈ $4.38 Billion	--

pp = percentage points

About GENMAB AS SP.ADR/1/10DK 1

F:GE91 Germany Biotechnology

Market Cap

$17.14 Billion

€14.66 Billion EUR

Market Cap Rank

#1631 Global

#351 in Germany

Share Price

€23.80

Change (1 day)

+3.48%

52-Week Range

€17.00 - €29.80

All Time High

€44.40